Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogenesis of atherosclerosis.

Mark A Crowther1

  • 1Joseph's Hospital, 50 Charlton Ave. East, Hamilton, Ontario, Canada L8N 4A6. crowthrm@mcmaster.ca

Hematology. American Society of Hematology. Education Program
|November 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of direct oral anticoagulants in patients with liver cirrhosis: a meta-analysis.

Research and practice in thrombosis and haemostasis·2026
Same author

Genetic and epigenetic dysregulation of CR1 is associated with catastrophic antiphospholipid syndrome.

Annals of the rheumatic diseases·2025
Same author

Efficacy of vitamin C with Fe supplementation in patients with iron deficiency anemia: a systematic review and meta-analysis.

Blood vessels, thrombosis & hemostasis·2025
Same author

Genetic and Epigenetic Dysregulation of CR1 is Associated with Catastrophic Antiphospholipid Syndrome (CAPS).

medRxiv : the preprint server for health sciences·2025
Same author

Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation.

Thrombosis research·2024
Same author

Serial D-dimers after anticoagulant cessation in unprovoked venous thromboembolism: Data from the REVERSE cohort study.

Thrombosis research·2023
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Atherosclerosis is now understood to be driven by inflammation, not just lipid issues. New therapies targeting these inflammatory pathways offer revolutionary treatment options for this complex vascular disease.

Area of Science:

  • Cardiovascular Science
  • Inflammation Biology
  • Vascular Medicine

Background:

  • Atherosclerosis pathogenesis is shifting from a lipid metabolism disorder to an inflammatory insult.
  • The inciting inflammatory event precedes clinical manifestation by decades.
  • Understanding the cellular and cytokine-mediated changes in the vessel wall is crucial.

Purpose of the Study:

  • To highlight the evolving understanding of atherosclerosis pathogenesis.
  • To emphasize the development of novel, target-specific therapies.
  • To discuss the role of inflammation in initiating and propagating atherosclerosis.

Main Methods:

  • Review of current scientific literature on atherosclerosis.
  • Analysis of inflammatory pathways involved in disease progression.

Related Experiment Videos

  • Evaluation of emerging therapeutic strategies targeting inflammation.

    • Main Results:

    • Inflammation is identified as the primary initiator of atherosclerosis.
    • Cytokine-mediated events are essential for atherosclerotic lesion growth.
    • Current interventions address symptoms but not the underlying inflammatory process.

    Conclusions:

    • Atherosclerosis is fundamentally an inflammatory disease.
    • Novel anti-inflammatory therapies are revolutionizing treatment approaches.
    • Targeting inflammatory pathways offers a promising strategy for managing atherosclerosis.